<DOC>
	<DOCNO>NCT00327600</DOCNO>
	<brief_summary>AMP-005 Phase 1b/2 clinical trial design evaluate whether new drug , imexon , administer combination approve drug , dacarbazine ( DTIC ) , treatment patient stage III IV inoperable melanoma . The Phase 1b part study design determine whether two drug safely combine together , Phase 2 part study design provide additional safety data gain understand whether add imexon DTIC improve outcome melanoma patient versus finding prior clinical study DTIC alone .</brief_summary>
	<brief_title>Safety Efficacy Trial Imexon Plus DTIC Advanced Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Malignant melanoma ; inoperable stage III IV disease . Able perform activity daily live . A projected life expectancy least 4 month . If female , neither pregnant nursing . Willing use contraceptive prevent pregnancy . Blood cell count blood chemistry near normal range . Prior radiation permit . No serious illness . No active malignancy . No serious infection . No current drug therapy cancer steroid therapy . No prior chemotherapy stage III IV disease . Brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>